Exclusive: Life Sciences Investor Briefing - Destiny Pharma #DEST, Shield #STX & Open Orphan #ORPH Watch Now
I'm watching with a view to buying in at some point. Back when shares were around 6p, my plan was to buy in at around 3p but since then we've had results that were really problematic, principally because they made house broker forecasts look daft. If the house broker, with their access, can get it so wrong, that makes it unlikely I'm going to be able to forecast with any sort of confidence. If I can't produce a range of forecasts with a range pf probabilities, I can't value. If I can't value then it is not an investment, it is a pure gamble.
Without significant news , I can't see me investing until at least 18 months down the line when/if some faith has been restored on the trajectory of the business. I'll keep watching,
Good luck and take care.
According to a poster on ADVFN:
************* " ....Various commercial properties used by members of the group during the year are owned or part owned by Ric Traynor or his personal pension fund. Rent and service charges paid on those properties by entities within the group in the year totalled £13,458 (2018: £155,500). At 30 April 2019 £nil (2018: £nil) was payable in respect of these transactions.” Page 61 Annual report and accounts 2019 Begbies Traynor Group plc" "It appears that in FY 2018 and 2019 many of the properties were disposed of by the chairman’s pension fund. Consequently, in each case I request that the new terms and annual rent of the new lease be disclosed, where the tenant is a Begbies Traynor Group entity including any pre-agreed rental increases and the dates thereof. In the spirit of “high standards of corporate governance”, open and transparent disclosure I would ask you to populate the below table and send a copy to me by 18 september. Should you not do so I shall attend your company’s AGM - where I have been nominated as a proxy - on 19 September to raise these matters in front of other shareholders."
My interpretation of today's RNS-R:
"Dear shareholders. For many other companies, they would be dropping everything to seize this opportunity to make $hundreds of millions and help hundreds of thousands of people with head and neck cancer but. But we are Angle and we have three more advanced and bigger opportunities (breast, prostate & ovarian) that are each worth $billions and help millions of people so those will be our priority and that is why today's great news is announced just as an RNS-R and not an RNS. "
Other people have built companies on smaller promise than shown in today's RNS-R. Angle has so much promise that today's RNS-R is a side comment!
All in my humble opinion. Feel free to call me Rampy McRampface. I'm just calling it like I see it but one person's clarity is another person's ramp. Do your own research and decide (i) ramp or (ii) ridiculously good opportunity.
Hi dimi123. Thanks for your kind words. I wish well to all investors here. I wonder if a drop below 60p would be good for all in the long term in that it might prompt management to make a statement. Not in anyone's interest for a sustained period with the unanswered questions hanging over Begbies like a cloud. Generally, companies don't like commenting on this sort of thing so Begbies might need the share price to give them a little push. Hopefully the statement will satisfy all that there is no problem or confess to the problem and give a strong line on resolving it and making sure it doesn't undermine the progress of the company.
Good Luck All.
The share price has been a bit toppy so was always a risk that any bad news could have a strong impact. I sold out earlier this year but keep an eye on Beg as I'd like to get back in when the price is right. I don't think there is much money to be made buying these in the 70s, even if the Winnifrith stuff proves to be garbage. I'm a buyer below 60p subject to Begbies making a satisfactory statement dealing with the allegations.
A few journalists got high profile pieces into print yesterday without too much effort on the back of the Angle prostate cancer good news. They got into major papers and even the front page of The Times. They must be pleased. If I was a journalist I'd love to get a front page in a major paper and I'd now have Angle PLC RNS notifications set up for when the next news drops. And as we all know, there are plenty of research projects out there relying on Angle's Parsortix so the next great news could drop at any time.
Looking forward to the next cracking RNS. If the journalists miss it, the decline of journalism will be even worse than I thought it was!
The Times: "Angle, the British company that makes the test, said that it could be in private clinics within 18 months." As already discussed on here, Barts Cancer Institute are saying 3 - 5 years for the test to be in the NHS.
Amazing comment from the researchers who, lets note, are NOT employed by Angle. They are from Barts Cancer Institute. "As this is a single centre study, the results need to be further validated in other independent research centres before the CTC test is available either privately or on the NHS in the UK, which could take a further 3-5 years. Clearance by the US Food and Drug Administration could also take 3-5 years."
These researchers are not looking at this as an interesting laboratory achievement, they are talking about it as being clinically useful and are talking about how long it will take to get it into the NHS!
3-5 years is really nothing in terms of getting a new medicine/medical advance to market. And this market is huge "market potential for ANGLE estimated to be in excess of US $3 billion per annum globally" "Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide."
Redrow looking very undervalued in my humble opinion. So I've jumped in :-)
I'm expecting this to be quite volatile as people react & over-react to good/bad news about Brexit and the economy so it might be a good trading share.
After all the gyrations in the share price, I think we'll end up somewhere way above the current £6.
Consesus broker target 759p. https://www.sharesmagazine.co.uk/shares/share/RDW/broker-views.
I can justify over 800p to myself but putting in caution I get to about 750p which is then backed up by the broker targets.
No debt. Defined benefit pension scheme is small. Highly profitable. Strong balance sheet. Room to absorb big hits to the economy. What concerns do people have? It would be good to hear what they are so i can check my thinking.
Just give them the Cenkos note. Yes, you (or we) would state the positives more strongly but the potential buyers would (and should) discount that because of our vested interests and passions. The Cenkos note is pretty good and gives a compelling investment case. Most I would suggest you do is highlight some tasty bits from the Cenkos note to get them interested in reading the rest. Good luck.
One could argue anything at the moment. As per results presentation last week, the fundraise was oversubscribed. The daily volume on ANGLE is small so it is difficult for a serious investor to buy a meaningful holding hence why they were so interested in buying chunks in a fundraise. As the fundraise was oversubscribed, someone could argue that there is demand out there for large chunks of AGL and this would support your idea of a large buyer(s) sitting on the market.
An alternative point of view is that there is no significant news scheduled in the near term. There is FDA submission in Q4 this year, FDA approval early next. Trial results for another application early next. AGL always has a good chance of dropping significant news at any point - there are potential partnerships that could be announced plus any of the boffins using AGL in their research could publish market moving findings as they have done in the past. However, the point is, there is no SCHEDULED significant news for a little while. That being the case, impatient hot money, especially small investors trading AIM, can be expected to drift elsewhere in the short term. That could be used to argue an expectation for a short term price drift followed by recovery and further gains as scheduled news approaches or is reached.
Which ever way the share price twists in the short term, the greater significance is the incredible longer term potential for this company and its tech, should it come to fruition. I dream of sitting on my yacht spending my profits while boring people with how "my" ANGLE revolutionized cancer treatment around the world, saving lives, improving lives. Hmmmm... off to my happy place....
Paul McGlone, Seeing Machines CEO, asked in interview to list 3 reasons why investors should take interest. His 3rd reason: "Our business is considerably undervalued. Strong technology validated from global OEMs, airlines like Emirates and FedEx, and very very large fleets all around the world , the likes of National Express. So momentum is building and we are undervalued."
Way to go, Paul! I don't think I remember Ken ever stating so publicly that this share price is ridiculously low. That is one hell of a statement for a CEO to make publicly You don't hear it very often from any company.
Google "Paul McGlone Interview Seeing Machines Immotion"
If you are going to view the webcast, there might be some confusion with the start time. When I registered, I think it said it would be at 12:30 but the original RNS said it would be at 10:30. I'm going to get in there ready for 10:30.
So last Tuesday we got an auto contract woth "$11m-£30m" with scope to expand way beyond this with that auto brand.
This Tuesday we get a Fleet contract for 700 of NEG's vehicles with initial value I estimate at $2m-$3m with scope to expand across NEG's 30,500 vehicles. $2.5m x 30,500/700 is quite a big number.
Anyone else going to be at their PC at 7am next Tuesday, hoping for another very nice RNS? I could get to like Tuesdays!
Very nice. This initial contract for 700 vehicles is likely worth about $2m - $3m over the 4 year period starting this year. This initial contract is for deployment across specific brands in the UK. Exciting opportunity to expand to other National Express brands and across other National Express territories. National Express group operate 30,500 vehicles in total.
“The good news is the FDA has already confirmed the headline result that our study has been successful in harvesting cancer cells, from the blood of mastectomy breast cancer patients,” added Mr Newland.
“It has also shown that four major laboratory techniques analysing those cells work successfully."
“Angle is currently involved in finalising analytical studies to show the performance of our instrument – its reproducibility and a variety of other requirements for the FDA."